C4 Therapeutics (NASDAQ:CCCC) stock is heading higher on Tuesday as investors in the clinical-stage biopharmaceutical company celebrate a new license and research collaboration with Merck (NYSE:MRK).
This exclusive agreement with Merck has C4 Therapeutics working with it to develop degrader-antibody conjugates (DACs). These are an “emerging modality” designed for selectively targeting and neutralizing disease-causing proteins in cancer cells.
This agreement has C4 Therapeutics getting an upfront payment of $10 million from Merck. There’s also the potential for the company to get $600 million in milestone payments. To go along with that, C4 could get tiered royalties on future sales from the collaboration.
The collaboration will see C4 Therapeutics focus on using its Torpedo platform to develop degrader payloads in the discovery phase. Following that, Merck will handle “antibody conjugation” to create DACs in the discovery phase. It will also move them through clinical trials and into commercialization.
Andrew Hirsch, President and CEO of C4 Therapeutics, said the following about the news:
“We look forward to leveraging our powerful TORPEDO® platform in collaboration with Merck’s antibody-drug conjugation expertise to engineer novel medicines with the potential to transform patients’ lives.”
CCCC Stock Movement Today
With this collaboration agreement comes heavy trading of CCCC stock. As of this writing, more than 57 million shares have changed hands. For comparison, its daily average trading volume is about 572,000 shares.
CCCC stock is up 72% as of Tuesday morning.
Investors can find more of the hottest stock market news today below!
We have all of the latest stock market news worth reading about on Tuesday! That includes everything happening with shares of State Street (NYSE:STT), Wyndham Hotels (NYSE:WH) and Lucid (NASDAQ:LCID) stock today. You can catch up on that at the following links!
More Tuesday Stock Market News
- State Street Layoffs 2023: What to Know About the Latest STT Job Cuts
- Wyndham Hotels (WH) Stock Pops on Takeover Offer
- LCID Stock Alert: Lucid Announces CFO Departure
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
